Early-life associations between per- and polyfluoroalky longitudinal birth cohort

Environmental Research 200, 111400 DOI: 10.1016/j.envres.2021.111400

Citation Report

#	Article	IF	CITATIONS
1	Associations between Exposures to Perfluoroalkyl Substances and Diabetes, Hyperglycemia, or Insulin Resistance: A Scoping Review. Journal of Xenobiotics, 2021, 11, 115-129.	2.9	27
2	Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury. Environment International, 2021, 157, 106843.	4.8	108
3	Early-life exposure to perfluoroalkyl substances in relation to serum adipokines in a longitudinal birth cohort. Environmental Research, 2022, 204, 111905.	3.7	11
4	Perfluoroalkyl Substances and Abdominal Aortic Calcification. Journal of Occupational and Environmental Medicine, 2022, 64, 287-294.	0.9	3
5	Prenatal Exposure to Per- and Polyfluoroalkyl Substances and Child Growth Trajectories in the First Two Years. Environmental Health Perspectives, 2022, 130, 37006.	2.8	17
6	Understanding exposures and latent disease risk within the National Institute of Environmental Health Sciences Superfund Research Program. Experimental Biology and Medicine, 2022, 247, 529-537.	1.1	1
7	Health-related toxicity of emerging per- and polyfluoroalkyl substances: Comparison to legacy PFOS and PFOA. Environmental Research, 2022, 212, 113431.	3.7	30
8	Prenatal exposure to per- and polyfluoroalkyl substances and childhood adiposity at 7 years of age. Chemosphere, 2022, 307, 136077.	4.2	9
9	Childhood exposure to per- and polyfluoroalkyl substances and neurodevelopment in the CHARGE case-control study. Environmental Research, 2022, 215, 114322.	3.7	7
10	Exposure to a mixture of per-and polyfluoroalkyl substances modulates pulmonary expression of ACE2 and circulating hormones and cytokines. Toxicology and Applied Pharmacology, 2022, 456, 116284.	1.3	2
11	Cumulative maternal and neonatal effects of combined exposure to a mixture of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) during pregnancy in the Sprague-Dawley rat. Environment International, 2022, 170, 107631.	4.8	17
12	Perfluoroalkyl Substance Serum Concentrations and Cholesterol Absorption-Inhibiting Medication Ezetimibe. Toxics, 2022, 10, 799.	1.6	2
13	Transcriptional pathways linked to fetal and maternal hepatic dysfunction caused by gestational exposure to perfluorooctanoic acid (PFOA) or hexafluoropropylene oxide-dimer acid (HFPO-DA or) Tj ETQq0 0 0 r	gB I. 9Over	loalø10 Tf 50
14	In utero exposure to perfluoroalkyl substances and early childhood BMI trajectories: A mediation analysis with neonatal metabolic profiles. Science of the Total Environment, 2023, 867, 161504.	3.9	0
15	Per- and Polyfluoroalkyl Substances and Outcomes Related to Metabolic Syndrome: A Review of the Literature and Current Recommendations for Clinicians. American Journal of Lifestyle Medicine, 0, , 155982762311628.	0.8	4
16	Metabolic Signatures of Youth Exposure to Mixtures of Per- and Polyfluoroalkyl Substances: A Multi-Cohort Study. Environmental Health Perspectives, 2023, 131, .	2.8	19
17	Associations of prenatal PFAS exposure and early childhood neurodevelopment: Evidence from the Shanghai Maternal-Child Pairs Cohort. Environment International, 2023, 173, 107850.	4.8	12
18	A review of cardiovascular effects and underlying mechanisms of legacy and emerging per- and polyfluoroalkyl substances (PFAS). Archives of Toxicology, 2023, 97, 1195-1245.	1.9	12

#	Article	IF	CITATIONS
19	Probing the Interactions of Perfluorocarboxylic Acids of Various Chain Lengths with Human Serum Albumin: Calorimetric and Spectroscopic Investigations. Chemical Research in Toxicology, 2023, 36, 703-713.	1.7	5
20	Associations of perfluoroalkyl substances (PFAS) with lipid and lipoprotein profiles. Journal of Exposure Science and Environmental Epidemiology, 2023, 33, 757-765.	1.8	6

CITATION REPORT